Thermo Fisher Scientific (NYSE:TMO - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Sunday, Wall Street Zen reports.
Other analysts have also issued research reports about the company. Piper Sandler began coverage on Thermo Fisher Scientific in a report on Wednesday, September 9th. They issued an "overweight" rating and a $510.00 target price on the stock. Robert W. Baird upped their price target on Thermo Fisher Scientific from $723.00 to $756.00 and gave the stock an "outperform" rating in a report on Thursday, October 22nd. Citigroup raised their price objective on shares of Thermo Fisher Scientific from $685.00 to $800.00 and gave the stock a "buy" rating in a research note on Friday, October 23rd. UBS Group reaffirmed a "buy" rating and set a $800.00 target price (up from $540.00) on shares of Thermo Fisher Scientific in a research report on Thursday, October 22nd. Finally, CLSA assumed coverage on shares of Thermo Fisher Scientific in a research note on Thursday, September 3rd. They set an "outperform" rating and a C$748.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $683.64.
View Our Latest Stock Analysis on TMO
Thermo Fisher Scientific Stock Performance
Shares of TMO opened at $668.89 on Friday. The company has a market capitalization of $247.84 billion, a PE ratio of 35.28, a PEG ratio of 2.73 and a beta of 0.84. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.41 and a current ratio of 1.81. The company's 50 day moving average price is $678.63 and its 200 day moving average price is $559.30. Thermo Fisher Scientific has a 52 week low of $435.27 and a 52 week high of $727.56.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The company had revenue of $12.14 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same quarter in the prior year, the firm earned $5.79 EPS. The company's revenue was up 9.1% compared to the same quarter last year. Research analysts expect that Thermo Fisher Scientific will post 25.26 EPS for the current fiscal year.
Insider Activity at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 275 shares of the business's stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company's stock, valued at approximately $77,707,171.25. The trade was a 0.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 2,831 shares of the company's stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $706.45, for a total transaction of $1,999,959.95. Following the transaction, the vice president owned 11,560 shares in the company, valued at approximately $8,166,562. The trade was a 19.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.33% of the stock is owned by corporate insiders.
Institutional Trading of Thermo Fisher Scientific
Several institutional investors and hedge funds have recently made changes to their positions in the business. Kilter Group LLC bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $25,000. Allied Private Wealth LLC acquired a new position in Thermo Fisher Scientific during the second quarter valued at approximately $26,000. Compass Financial Management LLC grew its holdings in Thermo Fisher Scientific by 137.5% during the third quarter. Compass Financial Management LLC now owns 38 shares of the medical research company's stock valued at $26,000 after purchasing an additional 22 shares during the period. Pingora Partners LLC bought a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $30,000. Finally, Navigoe LLC bought a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $31,000. Institutional investors own 89.23% of the company's stock.
Trending Headlines about Thermo Fisher Scientific
Here are a few of the latest headlines about TMO:
Thermo Fisher Scientific Company Profile
(
Get Free Report)
Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.